AVGR - Week In Review: EurekaBio Raises $40M To Support Lentiviral Vector Platform

2024-03-10 03:55:00 ET

Summary

• Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its EuLV™ Lentiviral Vector Production System.
• Chengdu Maxvax Biotechnology raised $40 million in a Series C financing round to advance its portfolio of seven vaccines, two of which are in clinical trials.
• Hangzhou Zylox-Tonbridge entered a $15 million deal to distribute and manufacture the entire device line of California’s Avinger in China.

Deals and Financings

Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its EuLV™ Lentiviral Vector Production System, a technology that the company believes could transform large-scale production of lentiviral vectors. The system is based on stable cell lines and a serum-free suspension system. Eureka believes its novel technology will have a major impact in how cell and gene therapies are developed. The B+ round was led by Yeuxiu Industrial Fund, with participation from China funds and follow-on investments from US funds....

For further details see: